1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,211 | 0,290 | 22:59 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.05. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Minutes of the Annual General Meeting | 1 | Cision News | ||
| 13.05. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Notice of Annual General Meeting on 27 May 2026 | 2 | Cision News | ||
| 08.05. | ARCTIC BIOSCIENCE AS: Arctic Bioscience presents HeROPA data at EADV in Athens | 1 | Cision News | ||
| 07.05. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Annual report 2025 | 1 | Cision News | ||
| ARCTIC BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 30.04. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - 78% growth in Nutra revenues | 1 | Cision News | ||
| 24.04. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Invitation to presentation of Q1 2026 operational update | 2 | Cision News | ||
| 01.04. | Arctic Bioscience AS: Arctic Bioscience - New long-term financing | 1 | Oslo Børs | ||
| 01.04. | Arctic Bioscience AS: Arctic Bioscience - Primary insiders who have provided bank guarantee | - | Oslo Børs | ||
| 19.03. | Arctic Bioscience AS: Arctic Bioscience - New peer-reviewed study shows herring roe phospholipids stimulate anti-inflammatory pathways in cells | - | Oslo Børs | ||
| 26.02. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Q4 2025 Operational update - Positive outlook for 2026 | 3 | Cision News | ||
| 23.02. | Arctic Bioscience AS: Arctic Bioscience - Invitation to presentation of Q4 2025 operational update | 2 | Oslo Børs | ||
| 29.01. | ARCTIC BIOSCIENCE AS: Arctic Bioscience invited to present at the Glaucoma 360 New Horizons Forum | 3 | Cision News |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,66 | +0,08 % | Apogee Therapeutics: Hier dürfte zum US-Handelsstart heute die Post abgehen! | AbbVie steht laut einem Bericht kurz vor der Übernahme von Apogee Therapeutics für rund 10,9 Milliarden US-Dollar in bar. Der mögliche Aufschlag liegt bei etwa 60 Prozent. Weil die US-Börsen am Freitag... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 349,93 | +6,75 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 32,550 | +3,43 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| QIAGEN | 34,570 | +0,14 % | Qiagen und das KI-Thema | Die Analysten der DZ Bank sehen bei Qiagen viele aussichtsreiche Wachstumstreiber. Mittelfristig zeigen sich dadurch gute Perspektiven. Beim Thema KI profitiert Qiagen auf mehreren Ebenen, sei es bei... ► Artikel lesen | |
| VERA THERAPEUTICS | 43,130 | +1,58 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 109,43 | +1,21 % | Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? | OTTAWA (dpa-AFX) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which... ► Artikel lesen | |
| ERASCA | 18,290 | +14,24 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,740 | +1,68 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | - JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,340 | -0,37 % | Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? | ||
| MINERALYS THERAPEUTICS | 26,880 | +0,75 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 62,41 | +5,42 % | Kiniksa Pharmaceuticals Aktie markiert Rekordhoch bei 59,89 USD | ||
| ABSCI | 11,345 | +4,18 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,310 | +2,14 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| RELAY THERAPEUTICS | 19,740 | +6,36 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| BEAM THERAPEUTICS | 34,950 | +0,40 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen |
Das Unternehmen ARCTIC BIOSCIENCE AS kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,22 % bei einem Aktienkurs von 0,264 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCTIC BIOSCIENCE AS finden Sie auf Wallstreet Online.